CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call

Capricor Therapeutics Inc. stocks have been trading up by 17.98 percent after upbeat coverage highlighting ongoing exosome therapy momentum

Live Update At 09:18:44 EDT: On Wednesday, September 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 17.98%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) is trading like a typical small-cap biotech: volatile, catalyst-driven, and far from profitability. The daily chart shows CAPR drifting between roughly $8.30 and $9.50 over the past couple of weeks, with closes recently clustering in the high-$8 to low-$9 range. That tells traders the market is in “wait-and-see” mode after the initial upgrade pops.

Intraday, CAPR has printed strong swings, spiking above $11 premarket before fading back toward $10. That kind of range — more than $1 per share inside a single session — is classic day-trader territory. Liquidity appears decent, and the tape shows multiple push-and-pull attempts around whole-dollar levels like $10 and $11, key spots for breakout and fake-out moves.

Fundamentally, the numbers confirm this is a development-stage story. CAPR posted about -$40.7M in net loss last quarter, with a pretax margin of roughly -563% and negative returns on equity and assets. Yet the balance sheet carries a large cash and short-term investments position around $238M and a strong current ratio near 7.4, giving Capricor Therapeutics runway to fund deramiocel and other programs. For traders, CAPR is a binary catalyst play supported by a still-solid cash cushion.

Why Traders Are Watching CAPR Into The FDA Decision

CAPR has moved from niche biotech ticker to front-of-screen watchlist name thanks to a one-two punch from B. Riley and Piper Sandler. Both firms didn’t just nudge their views — they swung hard. B. Riley upgraded Capricor Therapeutics to Buy from Neutral and yanked its price target from $5 up to $21, explicitly flagging a favorable risk/reward ahead of the 2026/11/22 FDA action date for deramiocel. That is a massive reset of expectations.

Piper Sandler followed with its own upgrade on Capricor Therapeutics, shifting from Neutral to Overweight and hiking its target from $2 to $25. When a major broker multiplies its target more than tenfold, traders listen. This move centers on the same catalyst: the FDA’s extended action date for CAPR’s therapy deramiocel. Both shops are essentially saying the odds now skew more toward a positive outcome than the market had priced in.

The market didn’t shrug. CAPR jumped roughly 4–5% after the Piper Sandler call and again after B. Riley’s upgrade, proving that analyst headlines are actively moving the stock. Layer on top the Street’s broader Overweight stance and a mean price target near $31.78, and the message is clear: the analyst crowd, on average, sees substantial upside from current levels.

Then there’s the Schedule 13G. A significant passive stake in Capricor Therapeutics was disclosed, signaling that larger capital — not hot money — is quietly building a position. For active traders, that’s a confidence signal, but also a reminder that CAPR’s float may be tightening as we head toward October’s potential World Muscle Society data update and the November FDA decision.

Conclusion

For active traders, CAPR is shaping up as a textbook catalyst setup: strong pre-event run-up potential, real binary risk, and growing attention from Wall Street and larger holders. Capricor Therapeutics is still burning cash, posting negative earnings and heavy R&D spend, but its cash pile and low debt load give it time to chase value creation through deramiocel. That’s exactly why analysts are willing to plant aggressive flags with targets at $21, $25, and even a Street average near $31.78.

The price action already shows how sensitive CAPR is to headlines. A single upgrade has been enough to trigger 4–5% pops, and the intraday charts show wide swings around key levels. Traders who thrive on volatility will see Capricor Therapeutics as fertile ground — but the same volatility can punish slow reactions and oversized positions.

This is where discipline matters. As Tim Sykes loves to remind traders, “The market doesn’t care about your opinion, it only cares about price action and risk management.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. Apply that mindset to CAPR. Study the chart. Map the October conference and 2026/11/22 FDA dates. Know that the upside case many on the Street are pitching sits right next to serious downside if deramiocel disappoints. Use the bullish narrative around Capricor Therapeutics as a watchlist trigger, not a substitute for your own trading plan.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks